Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Braintact Ltd.

This article was originally published in Start Up

Executive Summary

Following a serious blow to the head, the initial damage to the brain may seem limited, but it's what happens afterwards that determines a victim's fate. Tragically, a few hours or even days later, the trauma may prove to have caused permanent or fatal damage. The amino acid neurotransmitter glutamate (Glu) plays a major role in the delayed but catastrophic reaction. Various pharmaceutical approaches to halting Glu-precipitated damage have thus far failed. Braintact proposes an entirely new way to treat TBI, stroke and even chronic brain diseases such as brain tumors. It seeks to lower the Glu levels in plasma without, however, touching the Glu release or receptor processes in the brain.

You may also be interested in...



Start-Up Previews (02/2008)

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Scaffolds in Tissue Engineering," features profiles of BioCeramic Therapeutics, Histogen, Humacyte and Tissue Regenix. Plus these Start-Ups Across Health Care: Braintact, CleveX, Coherex Medical and Lytix Biopharma.

Start-Up Previews (02/2008)

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Scaffolds in Tissue Engineering," features profiles of BioCeramic Therapeutics, Histogen, Humacyte and Tissue Regenix. Plus these Start-Ups Across Health Care: Braintact, CleveX, Coherex Medical and Lytix Biopharma.

Intelect Medical Inc.

Intelect Medical brings together a patent portfolio from the Cleveland Clinic and Cornell's Weill Medical College, and a management team experienced in neuromodulation, to usher in a new generation of deep brain stimulation. The start-up's initial target markets are traumatic brain injury and stroke.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PL007508

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel